Equity Overview
Price & Market Data
Price: $3.56
Daily Change: -$0.32 / 8.99%
Daily Range: $3.56 - $4.06
Market Cap: $198,288,144
Daily Volume: 44,229
Performance Metrics
1 Week: -5.80%
1 Month: -6.79%
3 Months: -2.72%
6 Months: -48.26%
1 Year: -55.65%
YTD: -46.32%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country:
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.